

P196 / #511

Topic: Theme A: β -Amyloid Diseases / A2.r. Therapeutic Targets, Mechanisms for Treatment: Other

MICROTUBULE STABILIZATION REDUCES AMYLOID PATHOLOGY AND IMPROVES SYNAPTIC/MEMORY DEFICITS IN APP/PS1 MICE

Lecture Title:

R. Sanchez-Varo¹, J.J. Fernandez-Valenzuela¹, C. Muñoz-Castro², V. De Castro¹, E. Sanchez-Mejias¹, V. Navarro², S. Jimenez², C. Nuñez-Díaz¹, A. Gomez-Arboledas¹, I. Moreno Gonzalez¹, F. Moyano², M.L. Vizuite², J.C. Davila¹, J. Vitorica², A. Gutierrez¹

¹University of Malaga/CIBERNED/IBIMA, Cell Biology, Genetic And Physiology, Malaga, Spain,

²University of Seville/CIBERNED/IBIS, Biochemistry And Molecular Biology, Seville, Spain

Aims: Cognitive decline in Alzheimer's disease (AD) is highly related to synaptic/neuronal loss. Tau hyperphosphorylation destabilizes microtubules leading to axonal transport failure and generation of dystrophic neurites, thus contributing to synaptic dysfunction. The effect of microtubule stabilization on amyloid- β (A β) pathology has not been assessed in vivo yet. This study evaluated the effect of the microtubule-stabilizing agent, EpopoD in the pathology of an amyloidogenic mouse model.

Methods: APP_{751SL}/PS1_{M146L} mice (3-month-old) were treated weekly with intraperitoneal injections of EpopoD (2 mg/kg) or vehicle for 3 months. For memory performance, animals were tested on the object-recognition, Y-maze and Morris water maze. Hippocampal proteinopathies were quantified by image analysis after immunostaining. Somatostatin (SOM)-numerical density was calculated by stereology. APP_{swe}-N2a cells were treated with EpopoD 100nM for 12/24 hours. Protein levels were analysed by Western/dot-blot.

Results: EpopoD-treated mice improved their performance of cognitive tests, while hippocampal phospho-tau and A β (especially oligomers) accumulation decreased, together with synaptic/neuritic pathology. Remarkably, EpopoD exerted a neuroprotective effect on SOM-interneurons, a highly AD-vulnerable GABAergic subpopulation.

Conclusions: EpopoD improved microtubule dynamics and axonal transport in an AD-like context, reducing tau and A β accumulation and promoting neuronal and cognitive protection, underlining the cross talk between cytoskeleton pathology and proteinopathy. Therefore, microtubule-stabilizing drugs could be candidates for slowing AD at both tau and A β pathologies. Supported by PI18/01557 (to AG) and PI18/01556 (to JV) grants from ISCIII of Spain, co-financed by FEDER funds (European Union), CIBERNED collaborative grant (to AG and JV), and by PPIT.UMA.B1.2017/26 grant (to RSV).